Pfizer and BioNTech vaccine (Image: Getty Images)
A study conducted by British researchers concluded that the first dose of the vaccine is against Covid-19 It increases protection against new variants of the Coronavirus, but only in people who have been previously infected.
According to the scientists who led the research at Imperial College London, Queen Mary University of London and University College London, the immune response to variants in those who have not yet developed the disease may be insufficient. The results of the work were published in Science on Friday, April 30.
“This study highlights the importance of the second dose of the vaccine to protect the population,” says Professor Rosemary Boyton, from the Department of Immunology and Respiratory Medicine at Imperial College London. During the study, specialists analyzed the immune responses of health workers in the United Kingdom after applying the first dose of an immunization agent produced by pharmaceutical companies. Pfizer E BioNTech.
The results of the research are related to coronavirus variants from South Africa and Kent, but scientists believe that the study’s conclusion also applies to other coronavirus strains circulating, such as those in Brazil and India.
Emily Brontë is a journalist and feature writer specialising in culture, entertainment, literature, and current affairs. She is dedicated to producing clear, accurate reporting that helps readers stay informed about developments in the UK and around the world.
